Genomas conducted a study with two of the leading atypical antipsychotic medicines.

Genomas published a paper in the January 2 on-line issue of Nature’s Molecular Psychiatry that highlights how understanding a patient’s DNA can predict an individual’s profile of risk or protection from the antipsychotic drugs prescribed, and thus provide clinicians with better options for drug selection or further preventative treatment.

Researchers looked at two leading atypical antipsychotic medicines on the market and found that a series of unique DNA variations could predict a patient’s likelihood for developing prediabetic side effects such as weight gain. 

The study, entitled “Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients”, was undertaken using Genomas’ PhysioGenomics Technology, a platform that analyzes DNA variation within a patient population and compares these differences to physiological characteristics or reactions.

Previous articleLilly In-Licenses OSI’s Diabetes Program for $25M
Next articleLGC to Market Human Genomic Reference Controls in India and Europe